About: Serum IgM against SARS-CoV-2 correlates with in-hospital mortality in severe/critical patients with COVID-19 in Wuhan, China

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Serum IgM against SARS-CoV-2 correlates with in-hospital mortality in severe/critical patients with COVID-19 in Wuhan, China Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Serum IgM against SARS-CoV-2 correlates with in-hospital mortality in severe/critical patients with COVID-19 in Wuhan, China
Creator	Liu, Bo Liu, Xintian Su, Xi Zhang, Gangcheng Zhang, Zhenlu Zheng, Xuan Wu, Mingxiang
Source	Medline; PMC
abstract	Severe/critical patients with coronavirus disease 2019 (COVID-19) have become the central issue in the current global pandemic due to their high mortality rate. However, the relationship between antibody response and clinical outcomes has not been well described in this group. We conducted a single-center, retrospective, cohort study to investigate the relationship between serum immunoglobulin G (IgG) and IgM and clinical outcomes in severe/critical patients with COVID-19. Seventy-nine severe/critical patients with COVID-19 admitted in Wuhan Asia General Hospital in Wuhan, China during January 22, 2020 to March 6, 2020 were included. Serum antibodies were measured at day 25 (SD, 7) post illness onset. The median IgG titer was 113 (IQR 81-167) AU/ml, and IgM titer was 50 (IQR, 23-105) AU/ml. Patients whose IgM titer ≥ 50 AU/ml had higher in-hospital mortality (p=0.026). IgM titer ≥ 50 AU/ml was also correlated with higher incidences of Acute Respiratory Distress Syndrome (ARDS) and sepsis shock. Antibody remeasurements were performed in 42 patients, where IgM titer declined significantly in survivors (p=0.031). Serum IgM titer changes according to the COVID-19 progression. The severe/critical patients with COVID-19 have a higher risk of clinical adverse events when IgM titer ≥ 50 AU/ml. Further decreasing of IgM could imply a better outcome in severe/critical cases.
has issue date	2020-07-06(xsd:dateTime)
bibo:doi	10.18632/aging.103417
bibo:pmid	32628642
has license	cc-by
sha1sum (hex)	46ff358bfff4a0700576fd6f66eba18f8d593c6e
schema:url	https://doi.org/10.18632/aging.103417
resource representing a document's title	Serum IgM against SARS-CoV-2 correlates with in-hospital mortality in severe/critical patients with COVID-19 in Wuhan, China
has PubMed Central identifier	PMC7377873
has PubMed identifier	32628642
schema:publication	Aging (Albany NY)
resource representing a document's body	covid:46ff358bfff4a0700576fd6f66eba18f8d593c6e#body_text
is schema:about of	named entity 'cases' named entity 'measured' named entity 'However' named entity 'COVID-19' named entity 'RELATIONSHIP' named entity 'ADMITTED' named entity 'THEIR' named entity 'PATIENTS' named entity 'POST' named entity 'CASES' named entity 'IGM' named entity 'ANTIBODY' named entity 'SHOCK' named entity 'PANDEMIC' named entity 'JANUARY' named entity 'SEPSIS' named entity 'ACCORDING' named entity 'OUTCOME' named entity 'CENTER' named entity 'CLINICAL' named entity 'CHANGES' named entity 'DAY' named entity 'Patients' named entity 'IgM' named entity 'cohort study' named entity 'survivors' named entity 'titer' named entity 'Asia' named entity 'Wuhan' named entity 'Wuhan' named entity 'Serum' named entity 'titer' named entity 'global pandemic' named entity 'clinical outcomes' named entity 'titer' named entity 'titer' named entity 'IgG' named entity 'COVID' named entity 'Serum' named entity 'IQR' named entity 'IgM' named entity 'COVID-19' named entity 'IgM' named entity 'antibody response' named entity 'serum' named entity 'titer' named entity 'COVID' named entity 'Wuhan' named entity 'China' named entity 'group' named entity 'ARDS' named entity 'computerized tomography' named entity 'Coronavirus disease 2019' named entity 'COVID' named entity 'study population' named entity 'SPSS' named entity 'Wuhan' named entity 'serum' named entity 'antibody' named entity 'IgM' named entity 'partial pressure' named entity 'titer' named entity 'underlying diseases' named entity 'antibody' named entity 'white blood cell count' named entity 'IgM' named entity 'CKD' named entity 'SARS-CoV-2' named entity 'prohormone' named entity 'Clinical Laboratory' named entity 'biomarkers' named entity 'COVID' named entity 'combination therapy' named entity 'COVID' named entity 'antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software